Dr. Suzan Davis

CEO, President & Founder
Dr. Davis is a pharmacist by training and holds a Master’s in Regulatory Affairs (MRA) and a Master’s in Business Administration (MBA) from Northeastern University.
With more than 24 years of experience in strategic planning, regulatory affairs strategy, regulatory submissions, clinical trial operations and management.
Dr Suzan S. Davis, President and CEO
As founder, President and CEO of Global Regulatory Partners Inc. (GRP), Dr. Suzan Davis provides the overall leadership, business strategy and day to day management at GRP. Her unique and extensive profile includes her experiences with various pharma, biotech and medical device companies. Her impressive international experience encompasses work in the United States, Europe, Latin America and Asia.
She has been directly involved in building Global Regulatory Partner’s team of highly motivated and talented professionals with the appropriate skills, expertise and experience in regulatory affairs, clinical, safety and quality.
Dr. Davis has more than 24 years of experience in strategic planning, regulatory affairs strategy, regulatory submissions, clinical trial operations and management, adverse event reporting and management, quality audits, licensing, CMC, technical transfer and business development within life sciences industry.
Dr. Davis assumed many leadership, senior management and consulting roles in large and small biotech, pharma and medical device companies such as GSK, Pfizer, Genzyme , EMD Sereno, Millennium/Takeda , Forum Pharmaceuticals, Olympus, Smith and Nephew in United States and international markets as well.
During her career, she managed many new products’ development projects and clinical trials in United States and outside United States. In addition to that, she prepared and submitted many IND, NDA, ANDA, BLA, IDE, 510(K), PMA, CE marking to FDA , EMA and other health authorities in Asia and Latin America.
As certified quality auditor by ASQ she conducted many GMP, ISO 13485 and due diligence audits for multiple pharmaceutical and medical device companies in United States, Europe, Asia and Latin America. She also helped many life science companies in the implementation and maintenance of their quality systems in compliance with FDA and ISO 13485 requirements.
Suzan Davis received a PharmD from pharmacy college (Université Paris 1 Panthéon-Sorbonne) in Paris, a Master in Regulatory Affairs (MRA) and a Master in Business Administration (MBA) from Northeastern University in Boston. She is also a certified quality auditor by ASQ , she is certified in US regulatory affairs ( RAC US) and certified in European regulatory affairs (RAC EU) by Regulatory Affairs Professional Society (RAPS).
Jason Faber

CHief Financial Officer
Dr. Davis is a pharmacist by training and holds a Master’s in Regulatory Affairs (MRA) and a Master’s in Business Administration (MBA) from Northeastern University.
With more than 24 years of experience in strategic planning, regulatory affairs strategy, regulatory submissions, clinical trial operations and management.
Chief Finance Officer
Yoshinori Shinoki
Japan Team
Japan General Manager
Mr. Yoshi Shinoki is a registered pharmacist with more than 35 years of experience in regulatory affairs and clinical research projects, areas in Japan.
Japan Team
Director of Regulatory & CMC
Mr. Tomoyuki Okamoto has over 30 years experience in vaccine development and is a CMC regulatory expert in Japan.
Complete Biography coming soon
Japan Team
Makoto Ishiwaki
SR. Regulatory Affairs Manager
Mr. Makoto Ishikawa has more than 30 years of experience in drug development and regulatory affairs in Japan.
Senior Regulatory Affairs Manager
Mr. Makoto Ishikawa has more than 30 years of experience in drug development and regulatory affairs in Japan.
Before joining Global Regulatory Partners GK Japan, as Sr. RA Manager, he was a Sr. RA Manager at Gene Therapy Research Institution Co., Ltd., where he performed Cartagena law submissions for 7 Gene therapy products (total 20 sites) and received the related approvals from MHLW. He managed orphan drug submissions to PMDA and conducted multiple consultation meetings with PMDA. Prior to that, he was the Safety Manager at CMIC Zero Japan, where he was in charge of reporting to PMDA serious adverse events (SAE) of different oncology products.
Mr. Makoto Ishikawa was also the Vice President of Regulatory Affairs Department at the Pharmaceutical Division, of Tobacco Inc. Tokyo Japan, where he managed the clinical development Regulatory Group, CMC Regulatory Group, and Document Management Group.
He was also responsible for the development and registration of different new drugs in Japan.
Prior to that, he managed the clinical development of anti-cancer, anti-hypertensive and antibiotics drugs at Roche Japan.
Mr. Makoto Ishikawa graduated from Nihon University, College of Agriculture and veterinary medicine with a Bachelor of veterinary medicine in 1978.